BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neuraxpharm readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Neuraxpharm's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05877963-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Briumvi (Ublituximab): Phase 3 readout est. (NCT05877963)
DESCRIPTION:Briumvi (Ublituximab)\, phase 3\, Multiple Sclerosis.\nStudy: S
 tudy to Evaluate Safety\, Efficacy and Pharmacokinetics (PK) of a Modified
  Regimen of Ublituximab\nEstimated primary completion: 21 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05877963
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503873-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07503873)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Multiple Sclerosis.\nStudy: A
  Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) U
 blituximab Administered at Various Injection Sites and Relative Bioavailab
 ility Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants 
 With Multiple Sclerosis (MS)\nEstimated primary completion: 31 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07503873
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673744-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07673744)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Myasthenia Gravis.\nStudy: A 
 Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Follo
 wing Induction With Efgartigimod Administration in Participants With Myast
 henia Gravis (MG)\nEstimated primary completion: 1 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07673744
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680946-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07680946)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Schizophrenia.\nStudy: Study 
 to Evaluate the Safety and Efficacy of Ublituximab in Participants With Sc
 hizophrenia\nEstimated primary completion: 12 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07680946
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220252-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Briumvi (Ublituximab): Phase 2/3 readout est. (NCT07220252)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2/3\, Multiple Sclerosis.\nStudy:
  Study to Assess Effects of Ublituximab in Pediatric Participants With Rel
 apsing Forms of Multiple Sclerosis\nEstimated primary completion: 1 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07220
 252
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04130997-6993@assetmemo.bio
DTSTAMP:20261120T230337Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Briumvi (Ublituximab): Phase 3 readout est. (NCT04130997)
DESCRIPTION:Briumvi (Ublituximab)\, phase 3\, Multiple Sclerosis.\nStudy: A
 n Extension Study of Ublituximab in Participants With Relapsing Multiple S
 clerosis\nEstimated primary completion: 31 May 2032. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04130997
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
